Abstract
Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.
Keywords: Spongistatins, Tubulin Targeting Agents, spiroketal pyrans (SPIKET), anticancer activity, SPIKET, SPIKET-P, anti-cancer drugs, Spiroketal Pyrans (SPIKET-P), Beta Tubulin, colchicine
Current Pharmaceutical Design
Title: Spongistatins as Tubulin Targeting Agents
Volume: 7 Issue: 13
Author(s): F. M. Uckun, C. Mao, S. -T. jan, H. Huang, A. O. Vassilev, C. S. Navara and R. K. Narla
Affiliation:
Keywords: Spongistatins, Tubulin Targeting Agents, spiroketal pyrans (SPIKET), anticancer activity, SPIKET, SPIKET-P, anti-cancer drugs, Spiroketal Pyrans (SPIKET-P), Beta Tubulin, colchicine
Abstract: Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.
Export Options
About this article
Cite this article as:
Uckun M. F., Mao C., jan -T. S., Huang H., Vassilev O. A., Navara S. C. and Narla K. R., Spongistatins as Tubulin Targeting Agents, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397492
DOI https://dx.doi.org/10.2174/1381612013397492 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design Synthesis, Cytotoxic Evaluation, and Molecular Docking Studies of N-(7- hydroxy-4-methyl-2-oxoquinolin-1(2H)-yl)acetamide/benzamide Analogues
Letters in Drug Design & Discovery Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Editorial
Current Medical Imaging RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Prebiotics: A New Hope Against Antibiotic Associated Diarrhea
Anti-Infective Agents Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications
Current Signal Transduction Therapy Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Drug Targets Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design